Neurophth Complete Enrollment for Leber’s Hereditary Optic Neuropathy Treatment

Neurophth Therapeutics has reached its enrollment objective for the early stages of their gene therapy prospect to treat Leber’s Hereditary Optic Neuropathy.  

The study is set to take place at multiple clinics across the US and will analyse the effectiveness and risks associated with the candidate.  

Other candidates in the Neurophths portfolio aim to treat conditions such as vascular retinopathy and optic neuroprotection.  

Li Bin, the head executive at Neurophth, stated, “We are very grateful for the trust and support of patients and their families, as well as the participation and dedication of all researchers, who played a key role in promoting the successful completion of Phase I/II clinical enrolment.”  

Biin went on to add, “In China, for global, we will work hard to promote China’s medical scientific research results to the world and provide solutions for global eye diseases. Patients bring more innovative gene therapies.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.